Inscobee Inc. - 12 May 2024 Form 4/A - Amendment Insider Report for Apimeds Pharmaceuticals US, Inc. (APUS)

Reporting relationship: 10%+ Owner
Issuer ticker: APUS
Reported as of: 12 May 2024
Net transaction value: $0
SEC form: 4/A - Amendment
Accepted by SEC: 21 Nov 2025, 21:26:11 UTC
Original report date: 14 May 2025
Next SEC filing: 14 May 2025
Source filing: View source filing
Reporting owner signature: /s/ Nelson Mullins Riley & Scarborough LLP, Attorney-in-Fact

Key filing fact

Inscobee Inc. filed Form 4/A - Amendment for Apimeds Pharmaceuticals US, Inc. (APUS) on 21 Nov 2025.

Key facts

This page summarizes Inscobee Inc.'s Form 4/A - Amendment filing for Apimeds Pharmaceuticals US, Inc. (APUS).
0 reported transactions and 0 derivative rows are listed below.
Accepted by SEC: 21 Nov 2025, 21:26.

Change

No earlier filing in this sequence is available for direct comparison.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4/A - Amendment disclosures.

View source filing

Reporting Owners (1)

CIK 0002057997 Primary reporting owner

Inscobee Inc.

Relationship: 10%+ Owner
Address: ROOM 613, DIGITAL-RO 130, 6F, GEUMCHEON-GU, SEOUL, KOREA, REPUBLIC OF
Signature: /s/ Nelson Mullins Riley & Scarborough LLP, Attorney-in-Fact
Signature date: 21 Nov 2025

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

APUS holding

Common Stock, par value $0.0001 per share

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 4,316,618
Date: 12 May 2024
Ownership: By Apimeds Inc.
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The shares of common stock are owned directly by Apimeds Inc. ("Apimeds Korea"), which is a wholly owned subsidiary of the reporting person. The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose.

SEC remarks

On May 14, 2025, the reporting person filed a Form 4 (the "Form 4"), which incorrectly reported that the reporting person had indirect beneficial ownership of a Convertible Promissory Note in the amount of $184,833 (the "Note") and the shares of common stock underlying such Note (the "Shares"), through Apimeds Korea. On June 11, 2025, the reporting person filed an amendment to the Form 4 (the "Original Amendment"), to report that the reporting person directly owned the Note and the Shares. The Original Amendment did not update the holdings of Apimeds Korea to reflect that the Note and the Shares were directly owned by the reporting person. This amendment is being filed solely to correct Apimeds Korea's reported holdings. For the avoidance of doubt, as of May 12, 2025, the reporting person had direct beneficial ownership of 2,099,747 shares of common stock and indirect beneficial ownership of 4,316,618 shares of common stock held by Apimeds Korea.